Author: maria

  • All
  • --
  • ---
  • -2022
  • 2022-2
  • 2022-2-2-2
  • 2022-deltia-tipoy
  • 2022-deltia-tipoy-2-2
  • 2022-deltia-tipoy-2-2-2-2
  • 2023-deltia-typou
  • 2023-deltia-typou-2-2
  • 2024
  • 257-2
  • 257-2-2-2
  • 266-2
  • Announcements
  • Consolidated Financial Results
  • deltia-tipoy
  • deltia-tipoy-2-2
  • deltia-tipoy-2-2-2-2
  • Distribution of Divident
  • Events
  • FAQ
  • General Meetings and Corporate Actions
  • Insiders Transactions Disclosures
  • Invitations
  • invitations-2
  • Presentations
  • Press Kits
  • Press Releases
  • Regulated Information
  • Results 2024
  • Share Capital Increase
  • Uncategorized

  Peania, March 7th 2019 - Lavipharm S.A., pursuant to Article 19 of the European Parliament Regulation No 596/2014 and its Board dated 16/04/2014, hereby informs the investment community that, on March 4th 2019, T & A Holdings (Luxembourg) Sarl, a company related to Lavipharm SA's...

  Peania, March 14, 2019 - Lavipharm S.A., pursuant to article 17 of the European Parliament and Council Regulation 596/2014 (EU) and its Board of Directors meeting held on 11.03.2019, hereby notifies the investor community that it will participate to the share capital increase amounting to...

  Peania, February 9th, 2018 - Lavipharm S.A., pursuant to Article 19 of European Parliament Regulation No 596/2014 and its Board dated 16/04/2014, hereby informs the investment community that on 07.02.2018, T & A Holdings (Luxembourg) sarl, a company related to Lavipharm SA's Executive Chairman, Mr....

  Peania, June 15th, 2018 - The Ordinary Annual Shareholders Meeting of Lavipharm SA took place on Friday, June 15th, at the company's headquarters in Peania, with a 54.48% quorum. During the Shareholders’ Meeting, the management team presented all topics of the agenda along with the Annual...

  Peania, June 29th 2018 - Lavipharm S.A., pursuant to Article 19 of European Parliament Regulation No 596/2014 and its Board dated 16/04/2014, hereby informs the investment community that on 28.06.2018, T & A Holdings (Luxembourg) sarl, a company related to Lavipharm SA's Executive Chairman, Mr....

  Paiania, September 28, 2018 – Lavipharm demonstrated a solid performance in the first half of 2018. Despite the significant increase of obligatory rebates and clawbacks that burdened the pharma industry, Lavipharm sustained its Turnover and profitability, both at a consolidated and at parent company levels. More...

  Peania, October 24th 2018 - Lavipharm S.A., pursuant to Article 19 of the European Parliament Regulation No 596/2014 and its Board dated 16/04/2014, hereby informs the investment community that T & A Holdings (Luxembourg) sarl, a company related to Lavipharm SA's Executive Chairman, Mr. Athanasios...

  Peania, December 6th 2018 - Lavipharm S.A., pursuant to Article 19 of the European Parliament Regulation No 596/2014 and its Board dated 16/04/2014, hereby informs the investment community that, on December 3rd, 2018, T & A Holdings (Luxembourg) sarl, a company related to Lavipharm SA's...

  Παιανία, 28 Απριλίου 2017 – Κατά το 2016, παρά τη μείωση της δημόσιας φαρμακευτικής δαπάνης, την περαιτέρω συμπίεση του κλάδου της Υγείας και τη συνεχιζόμενη αβεβαιότητα, η Lavipharm παρουσιάζει ενίσχυση του Κύκλου Εργασιών της, που προέρχεται κυρίως από τη σημαντική αύξηση των Πωλήσεων της εκτός...